A.P. Pharma to Hold APF530 Phase 3 Trial Results Conference Call September 30 at 9:00 a.m. Eastern
REDWOOD CITY, Calif.--(BUSINESS WIRE)--
A.P. Pharma, Inc. (NASDAQ: APPA), a specialty pharmaceutical company, will announce clinical trial results from its pivotal Phase 3 trial for APF530 for the prevention of chemotherapy induced nausea and vomiting (CINV) before the market opens on Tuesday, September 30, 2008.
The Company will hold an investment-community conference call beginning at 9:00 a.m. Eastern Time (6:00 a.m. Pacific Time) on Tuesday, September 30, 2008 to discuss the trial results and answer questions.
To participate in the live call by telephone, please dial (888) 803-8275 from the U.S., and for international callers, please dial (706) 634-1287. A telephone replay will be available for 48 hours by dialing (800) 642-1687 from the U.S., or (706) 645-9291 for international callers, and entering reservation number 66813306.
Individuals interested in listening to the conference call via the Internet may do so by visiting www.appharma.com. A replay will be available on the Company's Web site for 30 days.
About A.P. Pharma
A.P. Pharma is a specialty pharmaceutical company focused on the development of ethical (prescription) pharmaceuticals utilizing its proprietary polymer-based drug delivery systems. The Company's primary focus is the development and commercialization of its bioerodible injectable and implantable systems under the trade name Biochronomer(TM). Initial target areas of application for the Company's drug delivery technology include anti-nausea, pain management, anti-inflammation and DNA/RNAi applications. For further information visit the Company's web site at www.appharma.com.
Source: A.P. Pharma, Inc.